François Rieger, CEO, and Carole Nicco, Chief Scientific Officer, BioSenic, looks at the use of Arsenic as a novel API as a companion piece to our latest EPM Issue.
There are a number of novel APIs which are starting to make serious clinical advances. The use of a combined metalloid/metal treatment as an anti-inflammatory, immunomodulatory, and anti-fibrotic API is a new concept. This new type of nonsteroidal anti-inflammatory drugs (NSAIDs) with anticancer activity could potentially lead to a first-in-class medication and a curative therapy for severe autoimmune diseases, rather than the currently available palliative treatments to slow progression.